1Tanigawara Y, Aoyama N, Kita T, et al. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacterpylori. Clin Pharmacol Ther, 1999, 66:528-534.
2Wrighton SA, Stevens JC, Beckeer GW, et al. Isolation and characterization of human' liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch Biochem Biophys, 1993, 306:240-244.
3Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Clin Pharmacokinet, 1996, 31:9-13.
4De Morais SMF, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of Smephenytoin in humans. J Biol C'hem, 1994, 269:15419.
5De Morais SMF, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol, 1994, 46 : 594-599.
7Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther, 1999,13(Suppl 3):27-36.
